RAW DATA (part II) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated
Zhe Cheng — 2026-06-14T10:15:02Z · Open Access
figshare.32220351 · Figshare
TL;DR — A 11.46 GB supplementary data deposit (figshare.32220351, 12 file(s), liver) in the MASLD / NAFLD / NASH data lake. under-mined portal (Figshare).
0. Summary
Biological premise.
The following premise is sourced from the repository record (not fabricated).
Background: Epidemiological evidence consistently indicates that the risk of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and hepatic fibrosis associated with sweetener substitutes is markedly lower than that of traditional sweeteners. However, the mechanisms by which sweetener substitutes circumvent remain largely unexplored.
Objective: To systematically elucidate the key mechanism underlying the protective effects of sweetener substitutes against sweetener-induced MASLD and hepatic fibrosis.
Methods: Chemical structures were retrieved from pubChem, followed by target prediction and screening to identify the unique risky targets exclusively mediated by sweeteners. Disease targets were collected and intersected with the aforementioned risky targets for comprehensive network toxicological analysis. Molecular docking was performed to verify the binding affinity. Expression profiles of these targets in clinical specimens were analyzed using the GEO and HPA databases. A mouse model of MASLD with hepatic fibrosis was established, while hepatic transcriptome sequencing was applied to validate in vivo target expression patterns. In vitro models were constructed using steatotic HepG2 cells and activated LX-2 cells. Oil Red O staining, immunofluorescence, and RT-qPCR were employed to verify the abrogating effects of sweetener substitutes on sweetener-mediated aberrant target expression and cellular injury.
Results: A total of 111 risky targets specific to sweeteners were identified, among which 31 were associated with MASLD and 54 with hepatic fibrosis. Enrichment analysis revealed that the AMPK pathway, centered on FOXO1, SREBF1, and SCD, was the core cascade through which sweetener substitutes mitigate MASLD risk, while the growth hormone synthesis, secretion and action pathway, dominated by ITPR1 and SSTR2, was responsible for reducing hepatic fibrosis risk. Clinical database analysis, consistent with the mouse model, showed dysregulated expression of FOXO1 and SREBF1 in liver tissues of MASLD individuals, as well as that of ITPR1 and SSTR2 with increasing fibrosis severity. In vitro experiments demonstrated that sweeteners induced lipid accumulation in HepG2 cells, downregulated FOXO1, upregulated SREBF1, and activated LX-2 cells with enhanced ITPR1 and SSTR2 expression. In contrast, the main sweetener substitutes reversed these abnormalities.
Every file in this dataset is a supplementary data readout relevant to MASLD / non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), landed from Figshare.
Assay and processing.
Modality: supplementary data (repository subtype: supp-data). Tier-1 (must-have) for this modality = the processed tables behind the paper's claims + a sample/condition key; Tier-2 (recommended) = author analysis tables, annotation, code; Tier-3 (optional / raw) = raw signal underlying the processed tables. The Completeness line in each dataset block below states, measured from the landed files, which tiers are present.
Sources.
- figshare.32220351 — Figshare deposit (under-mined portal (Figshare)).
- PMIDs: none recorded in the index for this deposit.
| Disease | MASLD / NAFLD / NASH |
| Assay / modality | supplementary data — supp-data |
| Organisms | unspecified |
| Repository | Figshare |
| Accession | figshare.32220351 |
| Access | Public (open); files mirrored in this dataset's input/ folder. |
| Number of studies | 1 |
| Number of files | 12 |
| Total size | 11,458,628,067 bytes (≈ 11.46 GB) |
| License | CC BY 4.0 |
1. Datasets — sample sources, protocols, experiment design and metadata
Landed sources at a glance.
| Source | Access | Files |
|---|---|---|
| Figshare | public / OPEN-processed | 12 |
The deposit at a glance.
| Accession | Description | Organism | Samples | Scale |
|---|---|---|---|---|
| figshare.32220351 | under-mined portal (Figshare) | unspecified | n/a | 12 files · 11.46 GB |
figshare.32220351 — RAW DATA (part II) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated
Figshare record · 12 files · 11.46 GB
-
Sample source. unspecified material; MASLD/NAFLD/NASH context (under-mined portal (Figshare)).
-
Samples and retention. Sample count not declared in the repository index; see the per-sample metadata file(s) listed below.
-
Experiment design. Repository subtype: supp-data; disease context MASLD/NAFLD/NASH.
-
Metadata available. See the annotated file table below; per-sample metadata ships in the ISA-Tab / SDRF / metadata file(s) where present.
-
Files (annotated).
File What it is JZ25100538-N_B_N5526-0D-Poly-A289_N_B-N_B_N5526-0D-Poly-A289_N_B_combined_R1.fastq.gzData file JZ25100538-N_B_N5526-0D-Poly-A289_N_B-N_B_N5526-0D-Poly-A289_N_B_combined_R2.fastq.gzData file JZ25100536-N_B_N5526-0B-Poly-A38_N_B-N_B_N5526-0B-Poly-A38_N_B_combined_R1.fastq.gzData file JZ25100537-N_B_N5526-0C-Poly-A39_N_B-N_B_N5526-0C-Poly-A39_N_B_combined_R2.fastq.gzData file JZ25100536-N_B_N5526-0B-Poly-A38_N_B-N_B_N5526-0B-Poly-A38_N_B_combined_R1.fastq.gz.md5Data file JZ25100536-N_B_N5526-0B-Poly-A38_N_B-N_B_N5526-0B-Poly-A38_N_B_combined_R2.fastq.gzData file JZ25100536-N_B_N5526-0B-Poly-A38_N_B-N_B_N5526-0B-Poly-A38_N_B_combined_R2.fastq.gz.md5Data file JZ25100537-N_B_N5526-0C-Poly-A39_N_B-N_B_N5526-0C-Poly-A39_N_B_combined_R1.fastq.gz.md5Data file JZ25100537-N_B_N5526-0C-Poly-A39_N_B-N_B_N5526-0C-Poly-A39_N_B_combined_R2.fastq.gz.md5Data file JZ25100538-N_B_N5526-0D-Poly-A289_N_B-N_B_N5526-0D-Poly-A289_N_B_combined_R1.fastq.gz.md5Data file JZ25100537-N_B_N5526-0C-Poly-A39_N_B-N_B_N5526-0C-Poly-A39_N_B_combined_R1.fastq.gzData file JZ25100538-N_B_N5526-0D-Poly-A289_N_B-N_B_N5526-0D-Poly-A289_N_B_combined_R2.fastq.gz.md5Data file -
How this experiment became a dataset. figshare.32220351 resolved via the Figshare record API → 12 open file(s) fetched into this dataset's
input/folder → sizes verified on disk (11,458,628,067 bytes (≈ 11.46 GB)). -
Completeness (supplementary data). Present: primary data table(s). (Tiers per the matching modality skill; assessment measured from landed filenames/headers.)
2. Analyses this atlas supports
- Reuse the processed tables. Start from
JZ25100538-N_B_N5526-0D-Poly-A289_N_B-N_B_N5526-0D-Poly-A289_N_B_combined_R1.fastq.gz; combine with the per-sample metadata file to reproduce the deposit's headline numbers. - Cross-cohort MASLD integration. Combine this deposit (figshare.32220351) with other liver/MASLD datasets in the lake sharing the same modality for meta-analysis.
Reproduce. All files are in this dataset's input/ folder; the source of record is figshare.32220351 (https://figshare.com/articles/dataset/_/32220351). Re-fetch with the MASLD crawler (masld_download_pass.py --only figshare.32220351); sizes are verified on disk and recorded in this dataset's metadata.json.
Citation
Zhe Cheng. RAW DATA (part II) of "Sweetener Substitutes Circumvented Metabolic dysfunction-Associated. Figshare accession figshare.32220351. https://doi.org/10.6084/m9.figshare.32220351.v1
About this dataset
This 10x Genomics dataset provides single-cell gene expression from liver samples, with disease state recorded as MASLD/NAFLD/NASH.
Analyze it in Drylab
Open this dataset in Drylab and ask a question in plain language. The AI agent loads the files, runs the analysis in a ready sandbox and explains each result. A typical first pass:
- Load the filtered feature-barcode matrix (HDF5) and run quality control on counts, genes and mitochondrial reads per cell.
- Normalize, select variable genes, then cluster the cells and draw a UMAP.
- Annotate clusters with marker genes and compare the cell-type mix between conditions.
- Run differential expression between cell types or samples to characterize masld/nafld/nash biology.